Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 9 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 11452775

    Detection of arginine methylation of EGFR for prediction of resistance to therapy

    The Board of Regents of the University of Texas System · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  2. US 11453719

    Compositions and methods for treating cancer with anti-ROR1 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  3. US 11453640

    Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

    Northwestern University · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  4. US 11452709

    Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted
  5. US 11446332

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  6. US 11446397

    Gene therapy vectors for treating heart disease

    Tenaya Therapeutics, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  7. US 11439683

    Anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  8. US 11439632

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted
  9. US 11433131

    Adoptive cell therapy using spherical nucleic acids (SNAs)

    Northwestern University · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  10. US 11433143

    Nano-enabled immunotherapy in cancer

    The Regents of the University of California · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  11. US 11427646

    Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

    B CELL DESIGN · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  12. US 11426385

    Methods of improving cancer chemotherapy

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  13. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  14. US 11419898

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  15. US 11414489

    Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

    HALOZYME, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  16. US 11401506

    Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

    Board nf Regents The Inivercitvof Texas Cvctom · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  17. US 11397184

    Selection of patients for combination therapy

    Syndax Pharmaceuticals, Inc. · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  18. US 11395838

    Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

    The Board of Regents of the University of Texas System · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  19. US 11396647

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  20. US 11389480

    Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  21. US 11389432

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  22. US 11389481

    Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

    CRISPR THERAPEUTICS AG · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  23. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  24. US 11376324

    Sting activating nanovaccine for immunotherapy

    The Board of Regents of the University of Texas System · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted